MONECO Advisors LLC Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

MONECO Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 8.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 482 shares of the medical research company’s stock after selling 46 shares during the period. MONECO Advisors LLC’s holdings in Thermo Fisher Scientific were worth $285,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kovitz Investment Group Partners LLC grew its position in Thermo Fisher Scientific by 1,359.7% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 10,612 shares of the medical research company’s stock valued at $6,268,000 after buying an additional 9,885 shares during the last quarter. Marietta Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 4.3% in the first quarter. Marietta Wealth Management LLC now owns 12,912 shares of the medical research company’s stock valued at $7,626,000 after acquiring an additional 529 shares during the period. California State Teachers Retirement System lifted its holdings in Thermo Fisher Scientific by 0.6% in the fourth quarter. California State Teachers Retirement System now owns 708,079 shares of the medical research company’s stock valued at $472,459,000 after acquiring an additional 4,340 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 1.1% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 24,890 shares of the medical research company’s stock valued at $16,608,000 after acquiring an additional 262 shares during the period. Finally, Baystate Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 33.9% in the first quarter. Baystate Wealth Management LLC now owns 83 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 21 shares during the period. 87.48% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.0 %

Shares of NYSE:TMO opened at $590.26 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65. Thermo Fisher Scientific Inc. has a 1 year low of $497.83 and a 1 year high of $672.34. The stock has a market capitalization of $231.06 billion, a P/E ratio of 31.41, a PEG ratio of 1.84 and a beta of 0.83. The stock has a 50-day simple moving average of $549.03 and a 200-day simple moving average of $557.79.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its quarterly earnings results on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, topping the consensus estimate of $4.92 by $0.59. The firm had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. Thermo Fisher Scientific’s revenue for the quarter was up 18.3% on a year-over-year basis. During the same period in the previous year, the company posted $5.60 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Thursday, September 15th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 0.20%. The ex-dividend date is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.39%.

Analyst Ratings Changes

A number of research firms have commented on TMO. Barclays raised their target price on Thermo Fisher Scientific from $630.00 to $685.00 and gave the company an “overweight” rating in a report on Monday, August 1st. SVB Leerink raised their target price on Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a report on Friday, July 29th. Morgan Stanley raised their target price on Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, July 29th. Finally, Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $605.00 to $525.00 in a research note on Monday, April 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $661.08.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $589.76, for a total transaction of $5,897,600.00. Following the transaction, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at approximately $108,146,060.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $589.76, for a total value of $5,897,600.00. Following the transaction, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at approximately $108,146,060.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michel Lagarde sold 17,150 shares of the company’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $548.30, for a total value of $9,403,345.00. Following the completion of the transaction, the chief operating officer now directly owns 15,758 shares in the company, valued at $8,640,111.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,994 shares of company stock valued at $29,033,170. Corporate insiders own 0.43% of the company’s stock.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.